Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis
May 19, 2023
0
Intercept Pharmaceuticals Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics aimed at treating progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). On May 19, 2023, Intercept Pharmaceuticals, announced that NASDAQ has halted trading of the company’s common stock. Today’s Meeting Today, the …
